With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Opthea Limited Sponsored ADR (OPT – Research ...

US stocks rose for a third day in a row despite souring consumer confidence — and as investors weighed whether President ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Uncertainty about the scope of Trump's upcoming tariffs has investors treading carefully. Stocks soared on Monday amid signs ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Brian Hilberdink says he wasn’t looking for a new job when he got the call from Boehringer Ingelheim to join up as their new ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

How the culture distinguishes health care choices between natural based medicinal options and evidence-based ...

Eric Karas, Chief Commercial Officer, outlined the company's multi-pronged strategy to increase neffy adoption, focusing on education, payer coverage, and patient awareness. He noted that neffy ...